Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (551-560 of 761) with videos related to

Pageof 77
Sort By:
The American Journal of Cardiology|October 24, 2006
Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery diseaseEsther Bernardo, Dominick J Angiolillo, Celia Ramírez, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Journal of the American College of Cardiology|October 16, 2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseDominick J Angiolillo, Esther Bernardo, Manel Sabaté, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 29, 2006
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrelDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 26, 2022
The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromesAlp Aytekin, J J Coughlan, Gjin Ndrepepa, et al.
Frontiers in Medicine|June 6, 2024
Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitorSeung-Yul Lee, Jae Young Cho, Diana A Gorog, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
JACC. Asia|June 12, 2026
Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort StudyJun Hwan Cho, Seng Chan You, Hoseob Kim, et al.
Giornale Italiano Di Cardiologia (2006)|July 12, 2012
[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation]Roberta Rossini, Ezio Bramucci, Battistina Castiglioni, et al.
Journal of Cardiovascular Translational Research|December 28, 2013
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trialStefanie Schulz, Dominick J Angiolillo, David Antoniucci, et al.
Pageof 77

Showing results (551-560 of 761) with videos related to

Sort By:
Pageof 77
The American Journal of Cardiology|October 24, 2006
Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery diseaseEsther Bernardo, Dominick J Angiolillo, Celia Ramírez, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Journal of the American College of Cardiology|October 16, 2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseDominick J Angiolillo, Esther Bernardo, Manel Sabaté, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 29, 2006
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrelDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 26, 2022
The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromesAlp Aytekin, J J Coughlan, Gjin Ndrepepa, et al.
Frontiers in Medicine|June 6, 2024
Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitorSeung-Yul Lee, Jae Young Cho, Diana A Gorog, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
JACC. Asia|June 12, 2026
Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort StudyJun Hwan Cho, Seng Chan You, Hoseob Kim, et al.
Giornale Italiano Di Cardiologia (2006)|July 12, 2012
[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation]Roberta Rossini, Ezio Bramucci, Battistina Castiglioni, et al.
Journal of Cardiovascular Translational Research|December 28, 2013
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trialStefanie Schulz, Dominick J Angiolillo, David Antoniucci, et al.
Pageof 77